Synthesis, Characterization and Biological Activity of 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine Derivatives as the Epidermal Growth Factor Recepter Inhibitors

被引:0
作者
Sun, Bing [1 ]
Zhang, Jin [1 ]
Yin, Xiu'e [1 ]
Xu, Yue [1 ]
Zhang, Furong [1 ]
Huang, Yushu [1 ]
Wang, Jinhui [1 ]
Wang, Guoqing [1 ]
Hu, Chun [1 ]
机构
[1] Shenyang Pharmaceut Univ, Minist Educ, Key Lab Struct Based Drug Design & Discovery, Shenyang 110016, Peoples R China
来源
LATIN AMERICAN JOURNAL OF PHARMACY | 2016年 / 35卷 / 03期
基金
美国国家科学基金会;
关键词
anti-proliferative activity; EGFR; docking; synthesis; 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives; TYROSINE KINASE INHIBITOR; NONSMALL CELL LUNG; POTENT; EGFR; LOCALIZATION; ACTIVATION; EXPRESSION; ERLOTINIB; DESIGN; DOMAIN;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The epidermal growth factor receptor has become one of the targets of anticancer drug research and development because of its widely distribution in several human tumor cells including non-small cell lung cancer. Based on molecular docking, a novel series of 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives have been synthesized and their biological evaluation for anti-proliferative activities on the human pulmonary carcinoma cell line A549 and EGFR inhibitory activities in vitro has been finished. According to the screening result, the target compound 7-(4-ethoxyphenyl)-4-(4-methoxylbenzylamino)-5,6,7,8-tetrahydrobenzo [4,5] thieno [2,3-d] pyrimidine (6d) and 7-(4-hydroxyphenyl)-4-(4-methoxylbenzylamino)-5,6,7,8-tetrahydrobenzo[4,5]thieno [2,3-d]pyrimidine (8d) demonstrated significant anti-tumor activity, and the preliminary structure-activity relationships of the target compounds were summarized. They were worthy of further modification to obtain more potent anticancer candidate drugs.
引用
收藏
页码:570 / 577
页数:8
相关论文
共 25 条
[1]   Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer [J].
Barker, AJ ;
Gibson, KH ;
Grundy, W ;
Godfrey, AA ;
Barlow, JJ ;
Healy, MP ;
Woodburn, JR ;
Ashton, SE ;
Curry, BJ ;
Scarlett, L ;
Henthorn, L ;
Richards, L .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) :1911-1914
[2]  
Chen L., 2001, [No title captured], Patent No. [WO 01/74844, 2001-10-11, 0174844]
[3]   The 4-anilinoquinazoline class of inhibitors of the erb B family of receptor tyrosine kinases [J].
Denny, WA .
FARMACO, 2001, 56 (1-2) :51-56
[4]   A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours [J].
Eskens, Falm ;
Mom, C. H. ;
Planting, A. S. T. ;
Gietema, J. A. ;
Amelsberg, A. ;
Huisman, H. ;
van Doorn, L. ;
Burger, H. ;
Stopfer, P. ;
Verweij, J. ;
de Vries, Ege .
BRITISH JOURNAL OF CANCER, 2008, 98 (01) :80-85
[5]   2-AMINO-THIOPHENE AUS METHYLENAKTIVEN NITRILEN CARBONYLVERBINDUNGEN UND SCHWEFEL [J].
GEWALD, K ;
SCHINKE, E ;
BOTTCHER, H .
CHEMISCHE BERICHTE-RECUEIL, 1966, 99 (01) :94-&
[6]   PREVALENCE OF ABERRANT EXPRESSION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR IN HUMAN CANCERS [J].
GULLICK, WJ .
BRITISH MEDICAL BULLETIN, 1991, 47 (01) :87-98
[7]   Novel 4-anilinoquinazolines with C-7 basic side chains:: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors [J].
Hennequin, LF ;
Stokes, ESE ;
Thomas, AP ;
Johnstone, C ;
Plé, PA ;
Ogilvie, DJ ;
Dukes, M ;
Wedge, SR ;
Kendrew, J ;
Curwen, JO .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (06) :1300-1312
[8]   ERBB receptors and cancer: The complexity of targeted inhibitors [J].
Hynes, NE ;
Lane, HA .
NATURE REVIEWS CANCER, 2005, 5 (05) :341-354
[9]  
IBRAHIEM LI, 1989, J CHEM SOC PAKISTAN, V11, P227
[10]   Epidermal growth factor receptor: mechanisms of activation and signalling [J].
Jorissen, RN ;
Walker, F ;
Pouliot, N ;
Garrett, TPJ ;
Ward, CW ;
Burgess, AW .
EXPERIMENTAL CELL RESEARCH, 2003, 284 (01) :31-53